ArticleBMC geriatrics2026
Trends and expenditures in polypharmacy and hyperpolypharmacy among older adults in the United States, 2002-2017.
Article in BMC geriatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundPolypharmacy and hyperpolypharmacy are increasingly common among older adults and are associated with substantial clinical and economic burdens. Understanding trends in their prevalence and associated expenditures is essential to inform policy and targeted interventions. This study examines trends in the prevalence of polypharmacy and hyperpolypharmacy and their associated healthcare and medication expenditures among U.S. older adults from 2002 to 2017.
methodsThis retrospective cross-sectional study used data from the Medical Expenditure Panel Survey, a nationally representative survey of the noninstitutionalized U.S. POPULATION: The study included older adults aged 65 years or older. Medication burden was categorized as polypharmacy (5-9 medications) and hyperpolypharmacy (≥ 10 medications), determined annually based on prescription records. The primary outcomes were annual prevalence estimates of polypharmacy and hyperpolypharmacy. Secondary outcomes were total healthcare and prescribed medication expenditures.
resultsOur study included 61,402 adults aged 65 years or older representing a weighted population of 643 million person-years. Over 2002 - 2017, the prevalence of polypharmacy ranged from 35.1%-39.4%, while the prevalence of hyperpolypharmacy ranged from 12.5%-17.7%. Polypharmacy prevalence increased significantly until 2011 (+ 0.38%/year [0.23 ~ 0.53]; p<.001) and declined thereafter (-0.45%/year [-0.67~-0.23]; p<.001). Hyperpolypharmacy significantly increased until 2006 (+ 0.87%/year [0.14 ~ 1.59]; p=.023), with a non-significant stable period afterward. Subgroup analyses revealed a higher prevalence among individuals aged 75-84 years and among females. Asians exhibited a significant increase in polypharmacy (+ 0.83%/year [0.32 ~ 1.33]; p=.023). Total healthcare expenditures increased among individuals with polypharmacy after 2013 (+$1030/year [231 ~ 1829]; p=.016). Prescribed medication expenditures increased significantly among individuals with hyperpolypharmacy particularly after 2014 (+$939/year [319 ~ 1560]; p=.006).
conclusionPolypharmacy and hyperpolypharmacy remain highly prevalent among older adults in the U.S., with a significant growth in medication expenditures over time among those with hyperpolypharmacy. These findings highlight the critical need for ongoing monitoring and tailored prescribing optimization efforts targeting subgroups with the high prescribing burden to reduce the clinical and economic burdens of polypharmacy and hyperpolypharmacy in aging populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.